Combined or sequential treatment of advanced melanoma?
نویسندگان
چکیده
منابع مشابه
Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
From Coley's toxin to combination immune checkpoint inhibition, strategies to activate the immune system and generate anticancer immunity have been ongoing for well over a century. Over the past decade, the so-called immune checkpoint inhibitors, generally monoclonal antibodies that target key regulators of T-cell activation, emerged as the most effective immune-targeted agents. Pembrolizumab i...
متن کاملAdvanced skin melanoma – systemic treatment
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcom...
متن کاملTargeted treatment of advanced NRAS-mutated melanoma
NRAS-mutations most commonly in codon 61 (Q61R or Q61K) can be detected in around 20% of cutaneous melanomas and have been found more frequently in nodular primary melanomas and primary tumors from skin sites with chronic UV-exposure [1]. Also, patients with NRAS-mutated locally advanced or metastatic melanoma have been proposed to undergo a more aggressive disease course with an increased freq...
متن کاملTargeting KIT for Treatment Of Advanced Melanoma
This is a remarkable time for melanoma research and treatment. Before this year, approved agents available for the treatment of metastatic melanoma were limited to dacarbazine (DTIC) and interleukin-2 (IL-2), with benefits achieved in only a small minority of patients treated with either drug. In 2011, however, two new agents, ipilimumab (YervoyTM) and vemurafenib (ZelborafTM), were approved, w...
متن کاملContemporary surgical treatment of advanced-stage melanoma.
HYPOTHESIS The clinical treatment of patients with stage IV melanoma according to criteria of the American Joint Committee on Cancer (AJCC) is controversial because the 5-year survival rate is approximately 5%. Specific clinicopathologic factors are predictive of survival following curative surgery. DESIGN Cohort analysis of 1574 successive patients undergoing surgical resection of metastatic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nowotwory. Journal of Oncology
سال: 2019
ISSN: 2300-2115,0029-540X
DOI: 10.5603/njo.2019.0024